148 related articles for article (PubMed ID: 32124272)
1. Patient Satisfaction with CIMZIA
Bailey K; Mountian I; Bruggraber R; Sunderland K; Tilt N; Szegvari B
Adv Ther; 2020 Apr; 37(4):1522-1535. PubMed ID: 32124272
[TBL] [Abstract][Full Text] [Related]
2. Six months multicentre pilot open label single-arm study to evaluate patient experience, acceptability and satisfaction of switching certolizumab pegol from a prefilled syringe or autoinjection pen to an AVA® e-Device in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis patients.
Borrás-Blasco J; Vicente-Escrig E; Rodríguez-Lucena FJ; García-Monsalve A; Arroyo-Domingo E; Ferrando-Piqueres R; Casterá E; Navarro-Ruiz A
J Clin Pharm Ther; 2022 Dec; 47(12):2345-2349. PubMed ID: 36470844
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol.
Tatla D; Mountian I; Szegvari B; VanLunen B; Schiff M
Expert Opin Drug Deliv; 2020 Jun; 17(6):855-862. PubMed ID: 32239971
[TBL] [Abstract][Full Text] [Related]
4. A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol.
Pouls BPH; Kristensen LE; Petersson M; van den Bemt BJF; Ballerini L; Bruggraber R; Karlen H; Mountian I; van Bracht E; Wiegratz S; Jørgensen TS
Expert Opin Drug Deliv; 2020 May; 17(5):705-711. PubMed ID: 32154740
[No Abstract] [Full Text] [Related]
5. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
Deeks ED
BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
[TBL] [Abstract][Full Text] [Related]
6. Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies.
Domańska B; Stumpp O; Poon S; Oray S; Mountian I; Pichon C
Adv Ther; 2018 Jan; 35(1):100-115. PubMed ID: 29222625
[TBL] [Abstract][Full Text] [Related]
7. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
9. Usability of the Certolizumab Pegol Auto-Injection Device in Australian Patients with Chronic Rheumatic Diseases: Results from a Market Research Study.
Aw J; Griffiths H; Zochling J; Lanzafame A; Jordan A
Patient Prefer Adherence; 2021; 15():1469-1476. PubMed ID: 34234420
[TBL] [Abstract][Full Text] [Related]
10. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Domańska B; VanLunen B; Peterson L; Mountian I; Schiff M
Expert Opin Drug Deliv; 2017 Jan; 14(1):15-22. PubMed ID: 27801596
[TBL] [Abstract][Full Text] [Related]
11. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ).
Keininger D; Coteur G
Health Qual Life Outcomes; 2011 Jan; 9():2. PubMed ID: 21232106
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
[TBL] [Abstract][Full Text] [Related]
13. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
Dhillon S
Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
